Long-term recombinant porcine somatotropin (PST) treatment mitigates the responses to subchronic lipopolysaccharide in swine.
The effect of multiple lipopolysaccharide (LPS) challenges in swine undergoing long-term treatment with porcine somatotropin (PST) was determined. Changes in aspartate serine transaminase (AST) occurred only at 24h following the first LPS challenge dose (P<0.05), while PST treatment moderated any change from occurring. Nonesterified free fatty acid (NEFA) levels were elevated in PST treated animals for the first 3 days following daily LPS treatment (P<0.05), while LPS treatment alone had no effect on plasma NEFA levels. Plasma urea nitrogen (PUN) levels were unchanged by LPS following the initial LPS challenge, but were decreased following the second challenge dose (P=0.014). These changes were long lasting, with a return to normal PUN levels not evident until Day 6. The PST treatment mitigated changes in PUN (P<0.05) when LPS was administered. Haptoglobin plasma levels, along with lipid peroxide production were not affected by LPS challenge or PST administration. LPS challenge reduced the levels of immunoreactive heat shock protein 70 (HSP70) throughout the entire challenge period (P<0.001). PST-LPS animals had normal levels of this protein. The results of the present study demonstrate that long-term PST treatment mitigates the adverse effects of subchronic LPS administration.
Myers
M J
MJ
Division of Animal Research, US FDA, Center for Veterinary Medicine, 8401 Muirkirk Road, Laurel, MD 20708, USA. mmyers@cvm.fda.gov
Farrell
D E
DE
Evock-Clover
C M
CM
Steele
N C
NC
D000818:Animals; D001219:Aspartate Aminotransferases / Q000097:blood; D001786:Blood Glucose / Q000032:analysis; D001806:Blood Urea Nitrogen; D005230:Fatty Acids, Nonesterified / Q000097:blood; D013006:Growth Hormone / Q000494:pharmacology*; D018840:HSP70 Heat-Shock Proteins / Q000097:blood; D006242:Haptoglobins / Q000032:analysis; D007328:Insulin / Q000097:blood; D015227:Lipid Peroxidation; D008070:Lipopolysaccharides / Q000008:administration & dosage*; D011994:Recombinant Proteins / Q000494:pharmacology; D013552:Swine / Q000097:blood*; D017392:Thiobarbituric Acid Reactive Substances / Q000032:analysis
D001786:Blood Glucose; D005230:Fatty Acids, Nonesterified; D018840:HSP70 Heat-Shock Proteins; D006242:Haptoglobins; D007328:Insulin; D008070:Lipopolysaccharides; D011994:Recombinant Proteins; D017392:Thiobarbituric Acid Reactive Substances; D013006:Growth Hormone; D001219:Aspartate Aminotransferases